852380-64-4

Upstream product

• 124-41-4 sodium methylate 
• 766529-94-6 (1R,3R,5R)-3-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-6-oxa-bicyclo[3.2.1]octane-4,7-dione 
• 665-27-0 1,5-quinide 
• 163217-18-3 (1R,3R,4S,5R)-3-[(tert-butyldimethylsilyl)oxy]-1,4-dihydroxy-6-oxa-bicyclo[3.2.1]octan-7-one 
• 77-95-2 D-(-)-quinic acid 

Downstream Products

• 852380-47-3 (1R,3R,5R)-3-Acetoxy-5-(tert-butyl-dimethyl-silanyloxy)-1-hydroxy-4-methylene-cyclohexanecarboxylic acid methyl ester 
• 1451070-67-9 (20S)-1α,3β-bis[(tert-butyldimethylsilyl)oxy]-2-methylene-25-[(triethylsilyl)oxy]-9,10-secocholesta-5(10),8-dien-6-yne 
• 1451070-71-5 (20S)-1α-[(tert-butyldimethylsilyl)oxy]-2-methylene-25-[(triethylsilyl)oxy]vitamin D₃ tert-butyl dimethylsilyl ether 
• 1428946-58-0 (20S)-1α,25-dihydroxy-2-methylene vitamin D₃ 
• 1428946-59-1 (5E)-(20S)-1α,25-dihydroxy-2-methylene vitamin D₃ 
• 213250-59-0 methyl (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-methylenecyclohexanecarboxylate 

Relevant academic research and scientific papers

SYNTHESIS AND BIOLOGICAL ACTIVITY OF 2-METHYLENE ANALOGS OF CALCITRIOL AND RELATED COMPOUNDS

Disclosed are 2-methylene analogs of vitamin D3 and related compounds, their biological activities, and various pharmaceutical uses for these analogs. Particularly disclosed are 1α-hydroxy-2-methylene-vitamin D3, (20S)-1α-hydroxy-2-m

Synthesis and Biological Activity of 2-Methylene Analogues of Calcitriol and Related Compounds

In an attempt to prepare Vitamin D analogues that are superagonists, (20R)- and (20S)-isomers of 1α-hydroxy-2-methyleneVitamin D3 and 1α,25-dihydroxy-2-methyleneVitamin D3 have been synthesized. To prepare the desired A-ring dienyne

2-methylene-vitamin D analogs and their uses

This invention discloses 2-methylene-vitamin D analogs, and specifically (20S)-1α,25 -dihydroxy-2-methylene-vitamin D3 as well as (5E)-(20S)-1α,25-dihydroxy-2 -methylene-vitamin D3 and (20R)-1α,25-dihydroxy-2-methylene-vitamin D

Development of an enantiodivergent strategy for the total synthesis of (+)- and (-)-dragmacidin f from a single enantiomer of quinic acid

An enantiodivergent strategy for the total chemical synthesis of both (+)- and (-)-dragmacidin F beginning from a single enantiomer of quinic acid has been developed and successfully implemented. Although unique, the synthetic routes to these antipodes share a number of key features, including novel reductive isomerization reactions, Pd(II)-mediated oxidative carbocyclization reactions, halogen-selective Suzuki couplings, and high-yielding late-stage Neber rearrangements.